Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Inclusion Criteria

• •Histological or cytological confirmation of a solid, malignant tumor or lymphoma that is refractory to standard therapies or for which no standard therapies exist
• •Patients must have received at least one prior systemic therapy
• •Measureable disease by RECIST v 1.1
• •ECOG PS 0 or 1
• •ANC \>= 1500/uL
• •Hgb \>= 9 g/dL
• •Platelets \>= 100,000/uL
• •AST/SGOT and ALT/SGPT =\< 2.5 x upper limit of normal (ULN) or =\< 5.0 x ULN in patients with liver metastases
• •Total Bilirubin =\< 1.5 times ULN
• •Creatinine =\< 2.0 mg/dL or Creatinine Clearance (calculated or 24 hour urine) \>= 50 ml/min
• •Female patients of childbearing potential must have a negative serum or urine pregnancy test =\< 21 days of study enrollment and agree to use an effective method of contraception for the duration of the study
• •Ability to understand and willingness to sign written informed consent
• •Unable to swallow whole pills
• •A requirement for one of the prohibited medications; if patient is currently taking one of these medications, they may be eligible so long as they discontinue the prohibited medication prior to starting study treatment and remain off for the duration they are taking study treatment
• •Known diagnosis of HIV
• •Concurrent malignancies are excluded with the following exceptions: basal cell skin cancer is allowed; cervical carcinoma in situ is allowed; any malignancy that does not require active treatment, and from which the patient has been disease free for \>= 3 years is allowed